Date: 2015-09-14
Type of information: Licensing agreement
Compound: multiple T cell receptor (TCR) gene sequences
Company: Kite Pharma (USA - CA) Netherlands Cancer Institute (NKI) (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: licensing collaboration
Action mechanism: cell therapy/immunotherapy product
Disease: solid tumors
Details: * On September 14, 2015, Kite Pharma announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI. Kite Pharma EU, based in Amsterdam , will be conducting preclinical research related to candidates under the agreement with NKI. Kite Pharma EU is comprised of a leading team of immuno-oncology researchers and collaborators, including Professor Dr. Ton N. M. Schumacher , who serves as Chief Scientific Officer of Kite Pharma EU. Professor Dr. Schumacher , a pioneer in T cell biology and gene therapy, is a developer of Kite\'s proprietary TCR-GENErator™ discovery platform, an industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates.
Financial terms:
Latest news:
